Lipocine is clinical-stage biopharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products focusing on neuroendocrine and metabolic disorders. Co. has a license agreement for the development and commercialization its product candidate, TLANDO®, an oral testosterone replacement therapy comprised of testosterone undecanoate. Co.'s additional pipeline candidates, LPCN 1148 comprising a prodrug of testosterone, testosterone laurate, for the management of decompensated cirrhosis. Co. is conducting a Phase 2 POC study in male cirrhotic subjects to evaluate the therapeutic potential of LPCN 1148 for the management of sarcopenia. The LPCN YTD return is shown above.
The YTD Return on the LPCN YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether LPCN YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the LPCN YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|